Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Cash & Equivalents (2020 - 2024)

RAPT Therapeutics' Cash & Equivalents history spans 5 years, with the latest figure at $37.8 million for Q3 2024.

  • For Q3 2024, Cash & Equivalents fell 30.23% year-over-year to $37.8 million; the TTM value through Sep 2024 reached $37.8 million, down 30.23%, while the annual FY2023 figure was $47.5 million, 21.91% up from the prior year.
  • Cash & Equivalents for Q3 2024 was $37.8 million at RAPT Therapeutics, up from $37.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $91.5 million in Q1 2020 and bottomed at $20.2 million in Q3 2020.
  • The 5-year median for Cash & Equivalents is $38.9 million (2022), against an average of $43.9 million.
  • The largest YoY upside for Cash & Equivalents was 197.75% in 2021 against a maximum downside of 72.99% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $24.9 million in 2020, then dropped by 3.58% to $24.0 million in 2021, then skyrocketed by 62.09% to $38.9 million in 2022, then grew by 21.91% to $47.5 million in 2023, then decreased by 20.45% to $37.8 million in 2024.
  • Per Business Quant, the three most recent readings for RAPT's Cash & Equivalents are $37.8 million (Q3 2024), $37.1 million (Q2 2024), and $45.3 million (Q1 2024).